Sage Group Advises Fabre-Kramer Pharma on Partnering Deal with Aytu Biopharma for EXXUA(TM), a Newly Approved and Innovative Treatment for Major Depressive Disorder

Aytu BioPharma Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, announced the signing of an exclusive agreement to commercialize EXXUA (gepirone) extended-release tablets ("EXXUA") in the United States. Gepirone is a new chemical entity and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD) in adults.

The Sage Group advised Fabre-Kramer Pharmaceuticals on this transaction.

See full Press Release here

FKP Aytu PR June 6 2025.pdf

Download PDF • 1.51MB

.